The information contained in this section of www.ONIVYDE.com is intended for US
healthcare professionals only.
If you are a US healthcare professional, click “OK”
to continue. If you are not a US healthcare professional, click “Cancel” to return to the patient
and caregiver section of the site.
The first and only FDA-approved treatment, in combination with 5-FU/LV, for metastatic pancreatic cancer after gemcitabine-based therapy, proven to extend overall survival1SEE THE EVIDENCE
Most patients in the phase 3 NAPOLI-1 trial received ONIVYDE® + 5-FU/LV in first- and second-line metastatic pancreatic cancer after gemcitabine-based therapy1,2VIEW DETAILS
Liposomal irinotecan (ONIVYDE®) is the only Category 1 NCCN chemotherapy recommendation in post-gemcitabine metastatic pancreatic cancer3
*Liposomal irinotecan + 5-FU/LV is the only Category 1 National Comprehensive Cancer Network® (NCCN®) chemotherapy recommendation for patients with post-gemcitabine metastatic pancreatic cancer with good performance status and disease progression. Good performance status is defined as ECOG 0-1 with patent biliary stent and adequate nutritional intake.3 See the NCCN Guidelines for Pancreatic Adenocarcinoma for a complete list of recommended treatment options. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.REVIEW NOW
ONIVYDE® is encapsulated in a liposome with prolonged circulation1LEARN MORE
The safety profile of ONIVYDE® + 5-FU/LV was well-characterized in NAPOLI-1, the largest phase 3 trial in patients with metastatic pancreatic cancer with disease progression after gemcitabine-based therapy1,2,4SEE CLINICAL RESULTS
Tap into helpful resources on coverage, access, and reimbursement for patients and caregiversGET HELP
5-FU=fluorouracil; ECOG=Eastern Cooperative Oncology Group; LV=leucovorin.
**National Comprehensive Cancer Network® (NCCN®).
References: 1. ONIVYDE® [package insert]. Basking Ridge, NJ. Ipsen Biopharmaceuticals, Inc.; 2017. 2. Wang-Gillam A, Li C-P, Bodoky G, et al. Lancet. 2016;387:545-557. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pancreatic Adenocarcinoma V.3.2017. ©National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed November 2, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 4. Data on file #1. Basking Ridge, NJ. Ipsen Biopharmaceuticals, Inc.; 2015.
INDICATION AND IMPORTANT